Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

Rautenberg, Tamlyn; Siebert, Uwe; Arnold, Dirk; Bennouna, Jaafar; Kubicka, Stefan; Walzer, Stefan; Ngoh, C.A.

doi:10.3111/13696998.2013.864973

Cited by 6 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, different factors influence the deterioration of the disease and its overall survival. Because it is complicated to control the causes of breast cancer, early diagnosis along with a suitable treatment is an important strategy for prognosis improvement [ 11 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

et al. 2020

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women. and regrettably, this rate is increasing every year. One of the aspects of all cancers, including breast cancer, is the recurrence of the disease, which causes painful consequences to the patients. Moreover, the practical application of data mining in the field of breast cancer can help to provide some necessary information and knowledge required by physicians for accurate prediction of breast cancer recurrence and better decision-making. The main objective of this study is to compare different data mining algorithms to select the most accurate model for predicting breast cancer recurrence. This study is cross-sectional and data gathering of this research performed from June 2018 to June 2019 from the official statistics of Ministry of Health and Medical Education and the Iran Cancer Research Center for patients with breast cancer who had been followed for a minimum of 5 years from February 2014 to April 2019, including 5471 independent records. After initial pre-processing in dataset and variables, seven new and conventional data mining algorithms have been applied that each one represents one kind of data mining approach. Results show that the C5.0 algorithm possibly could be a helpful tool for the prediction of breast cancer recurrence at the stage of distant recurrence and nonrecurrence, especially in the first to third years. also, LN involvement rate, Her2 value, Tumor size, free or closed tumor margin were found to be the most important features in our dataset to predict breast cancer recurrence.

show abstract

Section: Introductionmentioning

confidence: 99%

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For this reason, we decided to calculate the costs assuming a fixed treatment duration of 6.1 months for all regimens. This approach was already used in a previous economic evaluation, and was validated by clinical experts (25). A possible alternative would have been to consider, for each regimen, progression-free survival as a proxy of the time on treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, we estimated the average treatment cost assuming fixed treatment duration for all regimens. This duration was assumed equal to 6.1 months, based on the opinion of a panel of clinical experts reported in a previously published economic evaluation (25).…”

Section: Methodsmentioning

confidence: 99%

A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Iannazzo

Distante

Lopatriello

2017

Global & Regional Health Technology Assessment

View full text Add to dashboard Cite

“…These drug regimens are the most widely used treatment for mCRC in 1L and 2L in Brazil, and they are described in most treatment guidelines for metastatic disease (Van Cutsem & Oliveira, 2009;Sobrero et al, 2008;Peeters et al, 2010;Rautenberg et al, 2014;Van Cutsem et al, 2007;Chari et al, 2006;Glimelius & Oliveira, 2008;Glimelius & Oliveira, 2009;Nordlinger et al, 2009;Nordlinger et al, 2007;Papamichael et al, 2009;Van Cutsem & Oliveira, 2008). …”

Section: Scenariosmentioning

confidence: 99%

“…Each scenario was evaluated based on median progression-free survival (PFS) data from randomized clinical trials and also on the estimated average treatment duration for each line from Rautenberg et al (2014). Data on treatment duration are described in Table 3.…”

Section: Treatment Durationmentioning

confidence: 99%

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

Weschenfelder¹,

Tsuchiya²,

Kim³

et al. 2016

JBES

View full text Add to dashboard Cite

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil ABSTRACTObjective: To compare the treatment costs of different sequences of regimens including monoclonal antibodies in metastatic colorectal cancer (CRCm) treatment for the Brazilian Supplementary Healthcare System. Methods: Sixteen scenarios were analyzed, each one comparing a sequence of bevacizumab TML plus an anti-EGFR therapy in the third-line with another sequence without bevacizumab TML (non-Bev TML) in patients with CRCm wild-type RAS. The anti-EGFRs cetuximab and panitumumab were included. The monthly and total costs of the therapeutic sequences were compared per patient. Results: The sequences with Bev TML were cost-saving in 50% of all scenarios, and especially observed over regimens starting with cetuximab in the first-line treatment. Regarding scenarios which the non-Bev TML sequences were less costly, they all started with bevacizumab followed by an anti--EGFR biologic drug. Conclusion: The Bev TML regimens were cost-saving compared to scenarios of non-Bev TML which started with cetuximab, and sequential use of bevacizumab beyond progression and the addition of an anti-EGFR biologic drug in the third-line for mCRC treatment. Considering the remaining scenarios in which Bev-TML was not cost-saving, those starting with Bev presented lower costs in total. Therefore, starting a treatment with bevacizumab seems to enable a more rational management of resource usage, as well as, to allow physicians to add a biologic drug in the third-line, potentially enhancing the long term management of wild-type RAS mCRC. RESUMOObjetivo: Comparar o custo de tratamento de diferentes sequências de regimes incluindo anticorpos monoclonais no tratamento de câncer colorretal metastático (CCRm) no Sistema de Saúde Suplementar Brasileiro. Métodos: Dezesseis cenários foram analisados, cada um comparando uma sequência de bevacizumabe TML (Bev TML) mais um anti-EGFR em terceira linha, com outra sequên-cia sem bevacizumabe TML (não-Bev TML). Os anti-EGFRs cetuximabe e panitumumabe forma incluídos. Os custos mensais e totais do sequenciamento terapêutico foram comparados por pacientes. Resultados: As sequências com Bev TML trouxeram economia de recursos em 50% de todos os cenários, e especialmente comparado aos regimes iniciando com cetuximabe em primeira linha de tratamento. Considerando os cenários em que os regimes não-Bev TML apresentaram menos custo, todos iniciaram o sequenciamento com bevacizumabe seguido de um medicamento biológico anti-EGFR. Conclusões: Os regimes Bev TML apresentaram economia de recursos comparado aos cenários com não-Bev TML que iniciaram com cetuximabe, apesar do uso de bevacizumabe em múltiplas linhas e da adição de medicamento biológico anti-EGFR em terceira linha no tratamen- Keywords

show abstract

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

Cited by 6 publications

References 32 publications

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer

A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

Contact Info

Product

Resources

About